两种抗血管内皮细胞生长因子药物联合小梁切除术治疗新生血管性青光眼的疗效比较

目的比较两种抗血管内皮细胞生长因子（VEGF）药物（雷珠单抗和康柏西普）联合小梁切除术治疗新生血管性青光眼（NVG）的疗效和并发症。方法选取接受治疗且术后至少接受1个月随访NVG 49例，根据使用不同抗VEGF药物，分为雷珠单抗组23例（23眼）和康柏西普组26例（26眼），观察2组治疗后的视力、虹膜新生血管消退情况。结果2组不同时点眼压差异均无统计学意义（P>0.05），术后1周、2周、3周、1个月均明显低于注药前和注药后（P < 0.01）。2组治疗后的视力、虹膜新生血管消退及并发症差异均无统计学意义（P>0.05）。结论玻璃体腔内注射抗VEGF药物联合小梁切除术是一种安全有效的治疗方式，在相似的疗效前提下，对新生血管性青光眼，康柏西普比雷珠单抗是一种更好的选择。

Effect comparison of two anti-vascular endothelial growth factor drugs combined with trabeculectomy in the treatment of neovascular glaucoma

ObjectiveTo compare the effects and complications between two kinds of anti-vascular endothelial growth factor(VEGF) monoclonal antibodies(ranibizumab and conbercept) in the treatment of neovascular glaucoma(NVG).MethodsFourty-nine NVG patients were divided into the leizumab group(23 cases) and conbercept group(26 cases) according to the treatment with different anti-VEGF drug, and the clinic data of two groups were retrospectively analyzed.ResultsThe differences of intraocular pressure(IOP) between two groups at different time-points were not statistically significant(P>0.05).The IOP in two groups after 1 week, 2 weeks, 3 weeks and 1 month of operation were significantly lower than that before and after injection(P < 0.01).After treatment, the differences of vision, iris neovascularization and complications between two groups were not statistically significant(P>0.05).ConclusionsThe intravitreal injection of anti-VEGF drugs combined with trabeculectomy is a safe and effective treatment.On the premise of similar efficacy, conbercept is a better choice than ranibizumab.